Jack Chu
Principal Scientist GSK
Jack is a Principal Scientist at GSK focused on early CMC drug substance development. His work centers on mRNA process development and optimization to bridge early and late stage CMC across programs. Beyond routine optimization, he evaluates how IVT raw materials affect final drug substance quality and identifies the critical quality attributes (CQAs) used to de risk material selection and scale up.
Seminars
Thursday 1st October 2026
Optimizing Raw Material Strategies for Robust & Scalable mRNA Manufacturing
12:00 pm
- Examining how differences in input components influence yield, consistency, and impurity profiles across mRNA manufacturing workflows
- Establishing control strategies to ensure consistency without restricting flexibility- defining specifications, sourcing approaches, and risk-based frameworks that maintain quality while supporting process optimization and platform development
- Embedding raw material considerations into next-generation platform design – ensuring approaches are adaptable across emerging modalities while enabling faster development timelines, improved robustness, and reduced cost of goods
